Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Summary of studies using DXA scanning in children with CKD. Some notable studies that have used DXA to study BMD in children with CKD (Pubmed search strategy: All English language papers from 2000 to 2018).LS, lumbar spine; TH, total hi; WB/TB, whole body/total body; WBLH/TBLH, whole body less head/total body less head; Tx, transplantation; BMD, bone mineral density; iPTH, intact parathyroid hormone; P, phosphate; HD, haemodialysis; PD, peritoneal dialysis; Ca, ,calcium; iCa, ionised calcium; ALP, alkaline phosphatase; GC, glucocorticoid; 25OHD, 25-hydroxy vitamin D; rhGH, recombinant human growth hormone; PINP, serum type I procollagen intact amino-terminal propeptide Authors, year | Population (n) | Age of population (years) | DXA | Key findings | Biochemical correlations | Limitations | Comments: Bakr, 2004 [124] | CKD5 and HD (65: 21 CKD5, 44 HD) | 3 to 16 | LS | 61.9% of pre-dialysis children had low LS BMD and 59.1% of HD patients. | LS Z-scores of the osteopenic children negatively correlated with P (p = 0.004), iPTH (p = 0.03), and ALP (p = 0.02).There was a positive correlation between LS Z-scores and 25OHD | The biochemical analysis only is done in children with low Z-scores |
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Publisher article type: review-article
Source: Publisher publication metadata.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?
Review / evidence synthesis · Pediatric Nephrology (Berlin, Germany) · 2019
Original publication title
Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?
© The Author(s) 2019
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Mineral and bone disorder in chronic kidney disease (CKD-MBD) is a triad of biochemical imbalances of calcium, phosphate, parathyroid hormone and vitamin D, bone abnormalities and soft tissue calcification. Maintaining optimal bone health in children with CKD is important to prevent long-term complications, such as fractures, to optimise growth and possibly also to prevent extra-osseous calcification, especially vascular calcification. In this review, we discuss normal bone mineralisation, the pathophysiology of dysregulated homeostasis leading to mineralisation defects in CKD and its clinical consequences.
Bone mineralisation is best assessed on bone histology and histomorphometry, but given the rarity with which this is performed, we present an overview of the tools available to clinicians to assess bone mineral density, including serum biomarkers and imaging such as dual-energy X-ray absorptiometry and peripheral quantitative computed tomography. We discuss key studies that have used these techniques, their advantages and disadvantages in childhood CKD and their relationship to biomarkers and bone histomorphometry. Finally, we present recommendations from relevant guidelines: Kidney Disease Improving Global Outcomes and the International Society of Clinical Densitometry: on the use of imaging, biomarkers and bone biopsy in assessing bone mineral density.
Given low-level evidence from most paediatric studies, bone imaging and histology remain largely research tools, and current clinical management is guided by serum calcium, phosphate, PTH, vitamin D and alkaline phosphatase levels only.
Authors’ abstract
Mineral and bone disorder in chronic kidney disease (CKD-MBD) is a triad of biochemical imbalances of calcium, phosphate, parathyroid hormone and vitamin D, bone abnormalities and soft tissue calcification. Maintaining optimal bone health in children with CKD is important to prevent long-term complications, such as fractures, to optimise growth and possibly also to prevent extra-osseous calcification, especially vascular calcification. In this review, we discuss normal bone mineralisation, the pathophysiology of dysregulated homeostasis leading to mineralisation defects in CKD and its clinical consequences.
Bone mineralisation is best assessed on bone histology and histomorphometry, but given the rarity with which this is performed, we present an overview of the tools available to clinicians to assess bone mineral density, including serum biomarkers and imaging such as dual-energy X-ray absorptiometry and peripheral quantitative computed tomography. We discuss key studies that have used these techniques, their advantages and disadvantages in childhood CKD and their relationship to biomarkers and bone histomorphometry. Finally, we present recommendations from relevant guidelines: Kidney Disease Improving Global Outcomes and the International Society of Clinical Densitometry: on the use of imaging, biomarkers and bone biopsy in assessing bone mineral density.
Given low-level evidence from most paediatric studies, bone imaging and histology remain largely research tools, and current clinical management is guided by serum calcium, phosphate, PTH, vitamin D and alkaline phosphatase levels only.
Publication and source details
Original title: Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?
A.D. Lalayiannis; N.J. Crabtree; M. Fewtrell; L. Biassoni; D.V. Milford; C.J. Ferro; R. Shroff
Pediatric Nephrology (Berlin, Germany) · 2019
© The Author(s) 2019https://creativecommons.org/licenses/by/4.0/Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Kidney Research UKTF_002_20161124http://dx.doi.org/10.13039/501100000405Kids Kidney ResearchKKR/Paed2017/01http://dx.doi.org/10.13039/501100000272National Institute for Health ResearchCareer Development FellowshipRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T19:34:42.935198+00:00
DOI: 10.1007/s00467-019-04271-1 · PMC7184042